Knop, S., Szarejko, M., Grząśko, N., Bringhen, S., Trautmann‐Grill, K., Jurczyszyn, A., . . . Goldschmidt, H. (2024). A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma. Wiley. https://doi.org/10.1002/jha2.968
Chicago Style (17th ed.) CitationKnop, Stefan, et al. A Phase 1b/2 Study Evaluating Efficacy and Safety of MP0250, a Designed Ankyrin Repeat Protein (DARPin) Simultaneously Targeting Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF), in Combination with Bortezomib and Dexamethasone, in Patients with Relapsed or Refractory Multiple Myeloma. Wiley, 2024. https://doi.org/10.1002/jha2.968.
MLA (9th ed.) CitationKnop, Stefan, et al. A Phase 1b/2 Study Evaluating Efficacy and Safety of MP0250, a Designed Ankyrin Repeat Protein (DARPin) Simultaneously Targeting Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF), in Combination with Bortezomib and Dexamethasone, in Patients with Relapsed or Refractory Multiple Myeloma. Wiley, 2024. https://doi.org/10.1002/jha2.968.